Reactome | sorafenib-resistant FLT3 mutants [plasma membrane]

Schema > DefinedSet > Entries

sorafenib-resistant FLT3 mutants [plasma membrane] Show undefined attributes

compartment	[Compartment:876] plasma membrane
consumedByEvent	[FailedReaction:R-HSA-9702623] sorafenib-resistant FLT3 mutants don't bind sorafenib - Homo sapiens
created	[InstanceEdit:9699524] Rothfels, Karen, 2020-09-14
crossReference	[DatabaseIdentifier:12020745] Mondo:0004992
dbId	9699530
disease	[Disease:1500689] cancer
displayName	sorafenib-resistant FLT3 mutants [plasma membrane]
hasMember	[EntityWithAccessionedSequence:R-HSA-9699448] FLT3 A627P [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9695722] FLT3 F691L [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9702900] FLT3 F691I [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9682290] FLT3 D835A [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9682313] FLT3 D835F [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9682304] FLT3 D835H [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9682323] FLT3 D835V [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9682353] FLT3 D835Y [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9695715] FLT3 D835del [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9702909] FLT3 A848P [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9699435] FLT3 Y842C [plasma membrane] - Homo sapiens [EntityWithAccessionedSequence:R-HSA-9699443] FLT3 Y842H [plasma membrane] - Homo sapiens
inDisease	true
literatureReference	[LiteratureReference:9699345] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors [LiteratureReference:9699279] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors [LiteratureReference:9699393] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia [LiteratureReference:9695648] Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD [LiteratureReference:9699271] Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia [LiteratureReference:9699384] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib [LiteratureReference:9702954] FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
maxDepth	2
modified	[InstanceEdit:9703028] Rothfels, Karen, 2020-10-03
name	sorafenib-resistant FLT3 mutants
schemaClass	DefinedSet
species	[Species:48887] Homo sapiens
stId	R-HSA-9699530

Referrals

(input)	[FailedReaction:R-HSA-9702623] sorafenib-resistant FLT3 mutants don't bind sorafenib
(diseaseEntity)	[EntityFunctionalStatus:9702626] loss_of_function of sorafenib-resistant FLT3 mutants [plasma membrane]

© 2026 Reactome

Cite Us!